evan weekli dose therapi video updat
figur biotech week review video updat
overal perform week xbi ibb nbi vs
best perform coverag galapago worst perform mirati
regeneron
begin earn season earn preview discuss thought
ahead earn along target price updat gilead vertex
increas asia presenc sarepta anti-bcma space
gener set us biotech posit result sentiment still seem good
follow strong finish drug price concern remain ipi/most favor nation
think substanti legisl unlik larg gain might suggest posit shift
sentiment investor rotat back hc still get sens biotech investor
cautiou year elect broader macro concern strong earn cycl good
guidanc could help allay fear would expect better perform given mani
compani benefit season chang ahead tradit lower sale insur plan
chang year-end overal elect may impact sentiment come rhetor drug
price believ biotech fundament remain strong driven product
statu non-u analyst us disclosur credit suiss seek busi compani cover research report result investor
awar firm may conflict interest could affect object report investor consid report singl factor make invest
tp us biosimilar commerci ramp
ahead consensu expect revenu cs vs factset con
non-gaap ep vs weve seen sign resili base busi led
enbrel may off-set under-perform repatha neulasta increas due
advanc pipelin could see softer guid new cfo want
give runway beat-and-rais year weve increas estim biosimilar
franchis throughout forecast light strong first quarter us sale
ahead consensu cs vs con
gilead tp potenti miss hiv revenu hiv revenu
cs vs factset think consensu expect
underappreci like cannib legaci hiv asset biktarvi absent broader strategi
rejuven long-term growth expect share weak assum hiv miss weve decreas
revenu royalti contract reflect appropri trajectori consist
prior quarter
vertex tp like anoth beat rais vertex project higher non-
gaap ep vs factset con slightli con rev vs
believ recent trikafta approv
us add patient mix ou
reimburs agreement
like start contribut top-line increas termin
valu assumpt account greater strateg emphasi develop
pipelin given new ceo strategi diversifi beyond cf revenu greater convict
vertex success develop novel non-cf asset futur
tp unchang ahead earn focu remain aducanumab
tecfidera ipr estim ahead earn cs vs con base oper
expens manag share buyback howev believ spinraza may under-perform cs
vs con due on-going impact zolgensma also expect result
tecfidera ipr februari given event expect share remain flat
slightli earningscommentari spinraza even posit unlik much stock
point remain cautiou aducanumab despit like key driver share
given data discrep believ drug momentum potenti gain fda approv
regeneron tp unchang dupix could drive upsid
alreadi seen eylea sale beat expect dupix also outperformkey
consensu expect sanofi collabor vs consensu
believ recent effort sanofi regeneron streamlin partnership could potenti yield
greater cost save increas effici long-term estim eylea outperform
consensu expect like overestim competit beovu potenti impact
healthcar reform forecast compound-annual-growth-rate growth vs con compound-annual-growth-rate declin
tp unchang in-lin jakafi estim us jakafi sale in-
line factset compani provid consensu cs vs continu
believ jakafi remain market leader myelofibrosi polycythemia vera near-
term potenti upsid less like believ current share price fairli valu opportun
peak us sale view investor seem less impress recent morphosi deal
follow announc last week addit color might help market warm
stori believ iclusig olumi royalti in-lin expect
neurocrin tp unchang ingrezza beat larg expect despit decent ingrezza
beat vs consensu announc ahead continu believ
current trade level fairli valu opportun get sens investor expect
ahead sell-sid consensu believ beat larg expect neurocrin also
benefit inventori due quarter end-purchas look orilissa royalti
slightli ahead expect cs vs continu expect broader headwind
em indic
galapago tp like quiet quarter adjust financi expens
assumpt reflect histor spend de-risk profil see reduc overal risk
compani go forward due gilead partnership though outlook remain neutral
rel basi peer believ may challeng compani deliv market
return given larg cash balanc competit filgotinib pipelin either challeng
indic develop ipf low visibl asset toledo
news week
read-through week roche/ptc announc risdiplam competitor spinraza met
primari endpoint phase firefish trial type sma patient believ differ
profil risdiplam encourag use launch pdufa fda could approv drug
earli roche/ breakthrough therapi design forecast ww spinraza
sale declin vs consensu risdiplam firefish
compani announc would buy astella remain stake joint
ventur japan would creat tokyo-bas independ unit name amgen kk wholli
own come follow present hc confer sf last week
outlin strateg vision increas compani presenc asia note recal
jv compani launch repatha even blincyto japan
regeneron weak share week believ could relat
commentari week drug price price index/most favor nation view
drug price like continu overhang elect believ signific legisl
unlik cours administr could discuss drug price upcom state union
speech februari
weak may also partli concern abrocitinib compar dupix
upcom phase jade compar trial data abrocitinib atop dermat expect earli
year recal trial compar drug dupix number endpoint recent investor
confer state impact itch rapid abrocitinib dupix
believ mechanist inhibit cover direct stimul itch
sarepta potenti read-through fda disclos sarepta golodirsen
indic potenti safeti risk shed light regulatori process divis
review aducanumab hard say read critic
safeti profil fda
bcma space continu heat gsk target bcma get prioriti review fda base
could first anti-bcma drug gsk pr base expert dinner host
continu believ substanti opportun new modal mm
beyond expert indic off-the-shelf therapi adc bispecif like
regeneron like uptak commun set
think gsk belantamab mafodotin efficaci enough consid use ocular toxic
ultim manag via steroid eye drop mean leav thrombocytopenia
ae manag around bispecif promis data still earli would like
visibl ae administr profil candid assign specif valu
charl martineau pm univers toronto compani mention price
evan seigerman certifi view express report accur reflect person view subject compani
secur part compens directli indirectli relat specif recommend view express
report
price rate histori inc amgn oq
signifi initi assumpt coverag
effect juli nc denot termin coverag
price rate histori inc biib oq
signifi initi assumpt coverag
effect juli nc denot termin coverag
charl martineau pm univers toronto price rate histori galapago nv glpg
signifi initi assumpt coverag
price rate histori inc gild oq
signifi initi assumpt coverag
effect juli nc denot termin coverag
price rate histori incyt corpor inci oq
signifi initi assumpt coverag
charl martineau pm univers toronto price rate histori inc nbix oq
signifi initi assumpt coverag
price rate histori oq
signifi initi assumpt coverag
effect juli nc denot termin coverag
price rate histori inc regn oq
signifi initi assumpt coverag
charl martineau pm univers toronto price rate histori roch rog
signifi initi assumpt coverag
price rate histori inc vrtx oq
signifi initi assumpt coverag
effect juli nc denot termin coverag
decemb analyst stock rate defin follow
outperform stock total return expect outperform relev benchmark next month
neutral stock total return expect line relev benchmark next month
under-perform stock total return expect under-perform relev benchmark next month
relev benchmark region decemb japanes rate base stock total return rel analyst
coverag univers consist compani cover analyst within relev sector outperform repres
attract neutral less attract underperform least attract invest opportun octob
canadian well european exclud turkey rate base stock total return rel analyst coverag univers
consist compani cover analyst within relev sector outperform repres attract neutral less
attract underperform least attract invest opportun latin america turkey asia exclud japan australia
stock rate base stock total return rel averag total return relev countri region benchmark india
bse sensex index prior octob canadian rate base stock absolut total return potenti
current share price rel attract stock total return potenti within analyst coverag univers australian
new zealand stock expect total return calcul includ roll dividend yield outperform rate assign
greater equal under-perform less equal neutral may assign
overlap rate rang allow analyst assign rate put context associ risk
prior may rang outperform under-perform rate overlap neutral threshold
oper juli
restrict certain circumst credit suiss polici and/or applic law regul preclud certain type commun
includ invest recommend cours credit suiss engag invest bank transact certain
circumst
rate nr credit suiss equiti research invest rate view stock secur relat
compani time
cover nc credit suiss equiti research provid on-going coverag compani offer invest rate
invest view equiti secur compani relat product
volatil indic stock defin volatil stock price move month least
past month analyst expect signific volatil go forward
charl martineau pm univers toronto analyst sector weight distinct analyst stock rate base analyst expect fundament and/or
valuat sector rel group histor fundament and/or valuat
overweight analyst expect sector fundament and/or valuat favor next month
market weight analyst expect sector fundament and/or valuat neutral next month
underweight analyst expect sector fundament and/or valuat cautiou next month
analyst coverag sector consist compani cover analyst within relev sector analyst may cover multipl sector
credit suiss distribut stock rate bank client
purpos nyse finra rate distribut disclosur requir stock rate outperform neutral under-perform
